Optimum Platelet Inhibition After Coronary Bypass Surgery
This study has been completed.
Sponsor:
Papworth Hospital
Information provided by:
Papworth Hospital
ClinicalTrials.gov Identifier:
NCT00262275
First received: December 5, 2005
Last updated: July 20, 2006
Last verified: March 2001
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.
| Condition | Intervention |
|---|---|
|
Ischemic Heart Disease |
Drug: Aspirin, Clopidogrel |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel |
Resource links provided by NLM:
Further study details as provided by Papworth Hospital:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.
Exclusion Criteria:
Preoperative exclusion criteria:
- patients who are have not stopped aspirin 7 days prior to surgery
- patients on concomitant NSAIDS
- patients with a previous history platelet disorders, splenectomy or haematological disorders
- patients with aspirin induced asthma
- patients with any contraindications to aspirin (GI bleed)
- patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
- Women of childbearing potential
- Patients of less than 18 years
- If informed consent cannot be obtained
- If for any reason the consultant surgeon or anaesthetist deems it to be appropriate
Operative exclusion criteria:
• Concomitant procedures
Postoperative exclusion criteria:
- patients who receive platelet transfusion
- patients who receive NSAIDS
- requirement for intra aortic balloon pump support
- failure of extubation within 24 hours
Contacts and Locations More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00262275 History of Changes |
| Other Study ID Numbers: | LREC 01/624 |
| Study First Received: | December 5, 2005 |
| Last Updated: | July 20, 2006 |
| Health Authority: | United Kingdom: National Health Service |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Heart Diseases Coronary Disease Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Aspirin Clopidogrel Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 21, 2013